Search hospitals > Alabama > Mobile
University of South Alabama Mitchell Cancer Institute
Claim this profileMobile, Alabama 36688
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Relapse
Conducts research for Breast cancer
130 reported clinical trials
13 medical researchers
Summary
University of South Alabama Mitchell Cancer Institute is a medical facility located in Mobile, Alabama. This center is recognized for care of Skin Cancer, Breast Cancer, Ovarian Cancer, Relapse, Breast cancer and other specialties. University of South Alabama Mitchell Cancer Institute is involved with conducting 130 clinical trials across 251 conditions. There are 13 research doctors associated with this hospital, such as Moh'd Khushman, Ahmed Abdalla, Teja Poosarla, MD, and Jennifer Scalici,, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Moh'd KhushmanWashington University School of Medicine1 year of reported clinical research
Studies Colorectal Cancer
Studies Pancreatic Cancer
8 reported clinical trials
17 drugs studied
Ahmed AbdallaUniversity of South Alabama Mitchell Cancer Institute1 year of reported clinical research
Studies Cancer
Studies Relapse
7 reported clinical trials
28 drugs studied
Teja Poosarla, MDUniversity of South Alabama Mitchell Cancer Institute9 years of reported clinical research
Studies Cancer
Studies Breast Cancer
5 reported clinical trials
15 drugs studied
Jennifer Scalici,, MDUSA Mitchell Cancer Institute2 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
5 reported clinical trials
8 drugs studied
Clinical Trials running at University of South Alabama Mitchell Cancer Institute
Ovarian Cancer
Cancer
Pancreatic Cancer
Endometrial Cancer
Gallbladder Cancer
Non-Small Cell Lung Cancer
Lymphoma
Skin Cancer
Relapse
Bile Duct Cancer
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
Neratinib or Neratinib + Palbociclib
for Cancer
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.
Recruiting1 award Phase 2
Palbociclib + Binimetinib
for Pancreatic Cancer
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.
Recruiting1 award Phase 210 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of South Alabama Mitchell Cancer Institute?
University of South Alabama Mitchell Cancer Institute is a medical facility located in Mobile, Alabama. This center is recognized for care of Skin Cancer, Breast Cancer, Ovarian Cancer, Relapse, Breast cancer and other specialties. University of South Alabama Mitchell Cancer Institute is involved with conducting 130 clinical trials across 251 conditions. There are 13 research doctors associated with this hospital, such as Moh'd Khushman, Ahmed Abdalla, Teja Poosarla, MD, and Jennifer Scalici,, MD.